Last reviewed · How we verify
Oxaphenamid (OSALMID)
Oxaphenamid (generic name: OSALMID) is a osalmid drug. It is currently in Phase 2 development.
Oxaphenamid works by binding to a specific target, although its exact mechanism of action is not yet fully understood.
Oxaphenamid, also known as osalmid, is a small molecule drug in the osalmid class. Its exact target is unknown, but it is being developed for potential therapeutic applications. The commercial status of osalmid is currently unclear, and it is not yet FDA-approved for any indications. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and approved indications are not yet established.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OSALMID |
|---|---|
| Drug class | osalmid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key fitting into a lock. Oxaphenamid is like the key, and the target is like the lock. When the key fits into the lock, it can change the way the lock works, which in this case, could potentially treat a disease or condition.
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Assessments of Osalmid in Multiple Myeloma (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaphenamid CI brief — competitive landscape report
- Oxaphenamid updates RSS · CI watch RSS
Frequently asked questions about Oxaphenamid
What is Oxaphenamid?
How does Oxaphenamid work?
What is the generic name of Oxaphenamid?
What drug class is Oxaphenamid in?
What development phase is Oxaphenamid in?
Related
- Drug class: All osalmid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing